Last reviewed · How we verify
Clindamycin Topical Gel 1%
Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby reducing acne-causing bacteria and decreasing inflammation in acne lesions.
Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby reducing acne-causing bacteria and decreasing inflammation in acne lesions. Used for Acne vulgaris (topical treatment), Bacterial skin infections (secondary indication).
At a glance
| Generic name | Clindamycin Topical Gel 1% |
|---|---|
| Sponsor | Jinnah Postgraduate Medical Centre |
| Drug class | Lincosamide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clindamycin is a lincosamide antibiotic that penetrates sebaceous follicles and suppresses Cutibacterium acnes (formerly Propionibacterium acnes), the primary bacterium involved in acne pathogenesis. By inhibiting bacterial protein synthesis, it reduces bacterial colonization and associated inflammatory mediators. The topical formulation delivers high local concentrations to affected skin while minimizing systemic exposure.
Approved indications
- Acne vulgaris (topical treatment)
- Bacterial skin infections (secondary indication)
Common side effects
- Dryness or peeling
- Erythema or irritation
- Oiliness or folliculitis
- Contact dermatitis
Key clinical trials
- Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris (PHASE4)
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields (PHASE2)
- Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations (NA)
- Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris (PHASE2)
- Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients (PHASE2)
- Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels (PHASE3)
- Intradermal LPS and Antibiotics (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clindamycin Topical Gel 1% CI brief — competitive landscape report
- Clindamycin Topical Gel 1% updates RSS · CI watch RSS
- Jinnah Postgraduate Medical Centre portfolio CI